Background/Aims: Increasing rates of overdose deaths involving opioid maintenance treatment (OMT) medications and particularly methadone have been observed concurrently with the implementation of liberal OMT strategies (i.e. minimum of control and high doses prescribed). This study examined methadone-related overdose deaths in a liberal OMT programme. Methods: Drug-overdose deaths (n = 130) with detection of methadone in Copenhagen, Aarhus, and Odense Municipality, Denmark, during the period 2008-2011 were identified from a registry. Cases with and without prescribed methadone as OMT were compared. Treatment delivery strategy among OMT-prescribed methadone cases was investigated. Results: Methadone was detected in 130 overdose deaths (71.4% of all overdose deaths). Among these, 63.1% were receiving methadone maintenance treatment. Of these, 79.3% had co-detection of benzodiazepines. Concomitant detection of heroin, non-prescribed benzodiazepines, and younger age were associated with having non-prescribed methadone in the toxicological findings (adjusted OR 3.1, 4.0 and 9.5, respectively). Of the decedents, 43.8% were prescribed a higher methadone dose than recommended (>120 mg daily), of which 80.0% did not have supervised intake of methadone. Conclusions: Liberal OMT access does not necessarily prevent overdose deaths overall. Prescription of higher doses of methadone combined with benzodiazepines may result in an increased risk of overdose for individuals in as well as outside OMT.

Keywords:
Methadone-related overdose deaths, Opioid maintenance treatment
1.
Clausen T, Anchersen K, Waal H: Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008;94:151-157.
2.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, García de Olalla P, de la Fuente L: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005;100:981-989.
3.
Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375:1014-1028.
4.
Wikner BN, Öhman I, Seldén T, Druid H, Brandt L, Kieler H: Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug Alcohol Rev 2014;33:491-498.
5.
Simonsen KW, Edvardsen HM, Thelander G, Ojanperä I, Thordardottir S, Andersen LV, et al: Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int 2015;248:172-180.
6.
Casati A, Sedefov R, Pfeiffer-Gerschel T: Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012;18:228-245.
7.
White JM, Irvine RJ: Mechanisms of fatal opioid overdose. Addiction 1999;94:961-972.
8.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug Treatment Overview for Denmark. EMCDDA, 2014. http://www.emcdda.europa.eu/data/treatment-overviews/Denmark (cited January 31, 2016).
9.
European Commission: A Review of the Legislation, Regulation and Delivery of Methadone in 12 Member States of the European Union. Luxembourg, European Commission, 1996.
10.
Frank VA, Bjerge B, Houborg E: Shifts in opioid substitution treatment policy in Denmark from 2000-2011. Subst Use Misuse 2013;48:997-1009.
11.
Frank VA, Bjerge B, Houborg E: Substitutionsbehandling i Danmark - de sidste 10 års forandringer og udfordringer. Stofbladet 2012;20:106-109.
12.
Skretting A, Rosenqvist P: Shifting focus in substitution treatment in the Nordic countries. Nord Stud Alcohol Drugs 2010;27:581-597.
13.
WHO Guidelines Approved by the Guidelines Review Committee: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, World Health Organization, 2009.
14.
Table HSR-3. Estimated Number of Clients in Methadone Treatment and of all Clients Receiving any Opioid Substitution Treatment (OST). Statistical Bulletin, 2013.
15.
Sundhedsstyrelsen (The Danish Health and Medicines Authority). Narkotikasituationen i Danmark 1999 (In Danish). Sundhedsstyrelsen, 1999.
16.
Kringsholm B, Kaa E, Steentoft A, Worm K, Simonsen KW: Deaths among drug addicts in Denmark in 1987-1991. Forensic Sci Int 1994;67:185-195.
17.
The Danish Health and Medicines Authority. The Drug Situation in Denmark. Copenhagen, The Danish Health and Medicines Authority, 2014. http://sundhedsstyrelsen.dk/en/news/2014/the-drug-situation-in-denmark (cited December 1, 2015).
18.
Simonsen KW, Christoffersen DJ, Banner J, Linnet K, Andersen LV: Fatal poisoning among patients with drug addiction. Dan Med J 2015;62:A5147.
19.
Vormfelde SV, Poser W: Death attributed to methadone. Pharmacopsychiatry 2001;34:217-222.
20.
Bernard JP, Havnes I, Slørdal L, Waal H, Mørland J, Khiabani HZ: Methadone-related deaths in Norway. Forensic Sci Int 2013;224:111-116.
21.
Clausen T: The Norwegian OMT program - benefits and challenges. Norsk Farm Tid 2014;10:39-42.
22.
Albion C, Shkrum M, Cairns J: Contributing factors to methadone-related deaths in Ontario. Am J Forensic Med Pathol 2010;31:313-319.
23.
European Monitoring Centre for Drug and Drug Addiction (EMCDDA). Drug-Related Deaths and Mortality - An Overview of the Methods and Definitions Used. Lisbon, EMCDDA, 2011. http://www.emcdda.europa.eu/stats11/drd/methods (cited October 16, 2015).
24.
Statistics Denmark. Population in Denmark 2015Q4 Copenhagen: Statistics Denmark, 2015. http://www.dst.dk/en/Statistik/emner/befolkning-og-befolkningsfremskrivning/folketal (cited January 12, 2016).
25.
Pedersen CB: The Danish civil registration system. Scand J Public Health 2011;39(7 suppl):22-25.
26.
Helweg-Larsen K: The Danish register of causes of death. Scand J Public Health 2011;39(7 suppl):26-29.
27.
Kildemoes HW, Sørensen HT, Hallas J: The Danish national prescription registry. Scand J Public Health 2011;39(7 suppl):38-41.
28.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norwegian Institute of Public Health, 2007.
29.
Lynge E, Sandegaard JL, Rebolj M: The Danish national patient register. Scand J Public Health 2011;39(7 suppl):30-33.
30.
Mors O, Perto GP, Mortensen PB: The Danish psychiatric central research register. Scand J Public Health 2011;39(7 suppl):54-57.
31.
Clausen T, Waal H, Thoresen M, Gossop M: Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009;104:1356-1362.
32.
Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S: Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103:462-468.
33.
Weimer MB, Korthuis PT, Behonick GS, Wunsch MJ: The source of methadone in overdose deaths in Western Virginia in 2004. J Addict Med 2011;5:188-202.
34.
Laberke PJ, Bartsch C: Trends in methadone-related deaths in Zurich. Int J Legal Med 2010;124:381-385.
35.
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L: Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
36.
Caplehorn JR: Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. Drug Alcohol Rev 1998;17:9-17.
37.
Waal H, Gossop M: Making sense of differing overdose mortality: contributions to improved understanding of European patterns. Eur Addict Res 2014;20:8-15.
38.
Wolff K: Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit 2002;24:457-470.
39.
Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J: The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003;98:995-1002.
40.
Tjagvad C, Petersen H, Thylstrup B, Biong S, Clausen T: Drug-Induced Deaths and Other Drug Related Deaths in Denmark, 2008-2011. Copenhagen, Norwegian Centre for Addiction Research (SERAF), 2014.
41.
Strang J, Hall W, Hickman M, Bird SM: Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010;341:c4851.
42.
Danish National Board of Health. Guidance on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependence: Danish National Board of Health, 2008. http://sundhedsstyrelsen.dk/publ/Publ2008/EFT/Substitbehl_en/Guide_Substtreatm_Drugabuse.pdf (cited October 1, 2015).
43.
Deering DE, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R, et al: Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav 2011;36:636-642.
44.
Brandt L, Unger A, Moser L, Fischer G, Jagsch R: Opioid maintenance treatment - a call for a joint European quality care approach. Eur Addict Res 2016;22:36-51.
45.
Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Püschel K: Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment? Forensic Sci Int 2000;113:449-455.
46.
Duffy P, Baldwin H: The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J 2012;9:3.
47.
Jones JD, Mogali S, Comer SD: Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125:8-18.
48.
Reisfield GM, Webster LR: Benzodiazepines in long-term opioid therapy. Pain Med 2013;14:1441-1446.
49.
Lee HY, Li JH, Wu LT, Wu JS, Yen CF, Tang HP: Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy 2012;7:11.
50.
Ritter A, Di Natale R: The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev 2005;24:347-352.
51.
Bell J: The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. Addiction 2010;105:1531-1537.
52.
Dole VP, Nyswander ME, Kreek MJ: Narcotic blockade. Arch Intern Med 1966;118:304-309.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.